You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

37 search results for: COPD

ERS 2023 | Heterogeneity of Inflammatory Pathways in <b>COPD</b>

expert video

ERS 2023 | Heterogeneity of Inflammatory Pathways in COPD

8 min

Pulmonology

Dr. Stephanie Christenson shares an overview of inflammatory pathways underlying COPD, including type 2 inflammation.

ERS 2024 | Understanding the Complex Pathophysiology of <b>COPD</b>

expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

6 min

Pulmonology

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

ERS 2024 | Unraveling the Role of Type 2 Inflammation in <b>COPD</b>

expert video

ERS 2024 | Unraveling the Role of Type 2 Inflammation in COPD

8 min

Pulmonology

Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.

ERS 2024 | The Role of IL-33 in <b>COPD</b> Patho and Its Impact on Disease Remodeling

expert video

ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling

15 min

Pulmonology

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

<b>COPD</b> and Asthma: What's the Difference and Is There a Link?

interactivity

COPD and Asthma: What's the Difference and Is There a Link?

5 min

Pulmonology

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

ERS 2024 | Perspectives From the Evolving Biologic Landscape in <b>COPD</b>

expert video

ERS 2024 | Perspectives From the Evolving Biologic Landscape in COPD

20 min

Pulmonology

Professor Alberto Papi presents the latest clinical data on current and emerging biologics for COPD with type 2 inflammation.

ERS 2023 | Contextualizing Clinical Presentation of <b>COPD</b> Through Disease Pathology

expert video

ERS 2023 | Contextualizing Clinical Presentation of COPD Through Disease Pathology

9 min

Pulmonology

Prof. Klaus Rabe shares an overview of the underlying pathology of COPD and the clinical consequences of pathologic changes.

expert video

ERS 2024 | A Breath of Fresh Air: A Greater Understanding of COPD With Type 2 Inflammation

45 min

Pulmonology

Professors Henrik Watz, Mona Bafadhel, and Alberto Papi discuss the pathophysiology of COPD with type 2 inflammation and review current and emerging biologic therapies

interactivity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

5 min

Pulmonology

Learn about the disease burden and heterogeneity of COPD.

videoanimation

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

4 min

Pulmonology

Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.

expert video

Exacerbations Lead to Worsening Lung Function

2 min

Type 2 Inflammation

Dr. Mario Castro discusses how COPD exacerbations can predict future exacerbations and lead to progressive lung function loss in COPD patients.

expert video

ERS 2024 | IL-33 A Promising Target

7 min

Pulmonology

Professor Klaus Rabe presents the latest clinical data on current and emerging biologic therapies targeting IL-33 in COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: DenmarkChange country/region